Forbes contributors publish independent expert analyses and insights. Bruce Japsen writes about healthcare business and policy. Abbott Laboratories $21 billion deal to acquire cancer test maker Exact ...
Abbott made one of the biggest deals in recent medtech history last week when it announced its plan to acquire Exact Sciences — maker of colon cancer screening test Cologuard — for $23 billion.
Abbott Laboratories (NYSE: ABT) agreed on Thursday to acquire cancer screening company Exact Sciences Corp (NASDAQ: EXAS) for $105 per common share, representing a total equity value of approximately ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback